Repository logo
 
Publication

The Demise of Multidrug-Resistant HIV-1: the National Time Trend in Portugal

2013-04Journal article Open access
Simple item page
dc.contributor.authorVercauteren, J
dc.contributor.authorTheys, K
dc.contributor.authorCarvalho, AP
dc.contributor.authorValadas, E
dc.contributor.authorDuque, LM
dc.contributor.authorTeófilo, E
dc.contributor.authorFaria, T
dc.contributor.authorFaria, D
dc.contributor.authorVera, J
dc.contributor.authorAguas, MJ
dc.contributor.authorPeres, S
dc.contributor.authorMansinho, K
dc.contributor.authorVandamme, AM
dc.contributor.authorCamacho, R
dc.date.accessioned2018-08-14T14:44:42Z
dc.date.available2018-08-14T14:44:42Z
dc.date.issued2013-04
dc.description.abstractOBJECTIVES: Despite a decreasing mortality and morbidity in treated HIV-1 patients, highly active antiretroviral treatment (HAART) can still fail due to the development of drug resistance. Especially, multidrug-resistant viruses pose a threat to efficient therapy. We studied the changing prevalence of multidrug resistance (MDR) over time in a cohort of HIV-1-infected patients in Portugal. PATIENTS AND METHODS: We used data of 8065 HIV-1-infected patients followed from July 2001 up to April 2012 in 22 hospitals located in Portugal. MDR at a specific date of sampling was defined as no more than one fully active drug (excluding integrase and entry inhibitors) at that time authorized by the Portuguese National Authority of Medicines and Health Products (INFARMED), as interpreted with the Rega algorithm version 8.0.2. A generalized linear mixed model was used to study the time trend of the prevalence of MDR. RESULTS: We observed a statistically significant decrease in the prevalence of MDR over the last decade, from 6.9% (95% CI: 5.7-8.4) in 2001-03, 6.0% (95% CI: 4.9-7.2) in 2003-05, 3.7% (95% CI: 2.8-4.8) in 2005-07 and 1.6% (95% CI: 1.1-2.2) in 2007-09 down to 0.6% (95% CI: 0.3-0.9) in 2009-12 [OR=0.80 (95% CI: 0.75-0.86); P<0.001]. In July 2011 the last new case of MDR was seen. CONCLUSIONS: The prevalence of multidrug-resistant HIV-1 is decreasing over time in Portugal, reflecting the increasing efficiency of HAART and the availability of new drugs. Therefore, in designing a new drug, safety and practical aspects, e.g. less toxicity and ease of use, may need more attention than focusing mainly on efficacy against resistant strains.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationJ Antimicrob Chemother. 2013 Apr;68(4):911-4.pt_PT
dc.identifier.doi10.1093/jac/dks470pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3030
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherOxford University Presspt_PT
dc.subjectAnti-HIV Agentspt_PT
dc.subjectHIV Infectionspt_PT
dc.subjectHIV-1pt_PT
dc.subjectHumanspt_PT
dc.subjectMutation, Missensept_PT
dc.subjectPortugalpt_PT
dc.subjectPrevalencept_PT
dc.subjectViral Proteinspt_PT
dc.subjectDrug Resistance, Viralpt_PT
dc.subjectCHLC MEDpt_PT
dc.titleThe Demise of Multidrug-Resistant HIV-1: the National Time Trend in Portugalpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage914pt_PT
oaire.citation.issue4pt_PT
oaire.citation.startPage911pt_PT
oaire.citation.titleJournal of Antimicrobial Chemotherapypt_PT
oaire.citation.volume68pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
J Antimicrob 2013.pdf
Size:
174.76 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

MED - Artigos